Functional studies have shown that downregulation of NR2F1-AS1 can attenuate the malignant phenotype of dormant breast cancer cells and sensitize them to chemotherapeutic agents, thereby improving therapeutic efficacy [26, 27]. Here, NR2F1 is linked to breast carcinoma.